📷 Image: Wikimedia Commons / Shagil Kannur
Health
Kerala SMA Scheme Scrutinized Over Generic Drug Trial Label
✍️ India Today
🗓 21 Oct 2026, 08:02 PM
👁 17
Questions have been raised regarding the labeling of a generic drug under Kerala's free Spinal Muscular Atrophy (SMA) treatment scheme, with critics pointing to its 'clinical trial' status.
Kerala's government initiative to provide free treatment for Spinal Muscular Atrophy (SMA) has come under scrutiny due to questions raised about the nature of the medication being distributed. Reports indicate that the generic drug supplied under the scheme carries a label identifying it as being in the 'clinical trial' phase, a detail that has sparked debate among medical experts and patient advocacy groups.
The core of the controversy lies in the distinction between a fully approved therapeutic drug and one still undergoing clinical evaluation. While the state government aims to ensure accessible care for SMA patients, the use of a drug marked for trials has led to inquiries regarding the regulatory compliance and safety protocols associated with its distribution.
Health officials and stakeholders are now expected to address these concerns to clarify the regulatory status of the generic drug. The situation highlights the ongoing challenges in balancing rapid access to life-saving treatments with strict adherence to pharmaceutical safety standards in public health schemes.
The core of the controversy lies in the distinction between a fully approved therapeutic drug and one still undergoing clinical evaluation. While the state government aims to ensure accessible care for SMA patients, the use of a drug marked for trials has led to inquiries regarding the regulatory compliance and safety protocols associated with its distribution.
Health officials and stakeholders are now expected to address these concerns to clarify the regulatory status of the generic drug. The situation highlights the ongoing challenges in balancing rapid access to life-saving treatments with strict adherence to pharmaceutical safety standards in public health schemes.